Evofem Biosciences, Inc. (EVFM)
OTCMKTS: EVFM · Delayed Price · USD
0.0168
+0.0026 (17.96%)
Apr 26, 2024, 3:58 PM EDT - Market closed
Evofem Biosciences Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Year | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 2.77 | 7.73 | 48.89 | 15.57 | 1.33 | 3.42 | 11.48 | 37.75 | 75.95 | 4.36 | Upgrade
|
| Short-Term Investments | 0 | 0 | 0 | 8.23 | 0 | 0 | 0 | 0 | 0 | 0 | Upgrade
|
| Cash & Cash Equivalents | 2.77 | 7.73 | 48.89 | 23.8 | 1.33 | 3.42 | 11.48 | 37.75 | 75.95 | 4.36 | Upgrade
|
| Cash Growth | -64.19% | -84.19% | 105.39% | 1689.77% | -61.08% | -70.23% | -69.59% | -50.30% | 1640.32% | -60.68% | Upgrade
|
| Receivables | 1.13 | 6.45 | 1.32 | 0.69 | 0.26 | 0 | 0 | 0 | 0 | 0 | Upgrade
|
| Inventory | 5.38 | 7.67 | 7.16 | 1.28 | 0.76 | 0 | 0 | 0 | 0 | 0 | Upgrade
|
| Other Current Assets | 3.43 | -2.62 | 40.36 | 0.66 | 0.13 | 0.61 | 1.03 | 1.98 | 0.93 | 0.14 | Upgrade
|
| Total Current Assets | 12.7 | 19.24 | 97.73 | 26.42 | 2.48 | 4.03 | 12.51 | 39.73 | 76.87 | 4.51 | Upgrade
|
| Property, Plant & Equipment | 8.35 | 11.17 | 11.19 | 0.55 | 0.59 | 0 | 0.11 | 0.19 | 0.02 | 0.02 | Upgrade
|
| Long-Term Investments | 0.8 | 0.8 | 0.8 | 0.25 | 0 | 0 | 0 | 0 | 0 | 0 | Upgrade
|
| Other Long-Term Assets | 3.32 | 0.29 | 0.25 | 1.07 | 0.94 | 0.09 | 0.2 | 0.2 | 0 | 0 | Upgrade
|
| Total Long-Term Assets | 12.46 | 12.26 | 12.24 | 1.87 | 1.53 | 0.09 | 0.31 | 0.39 | 0.02 | 0.02 | Upgrade
|
| Total Assets | 25.16 | 19.24 | 109.97 | 28.3 | 4.01 | 4.12 | 12.82 | 40.11 | 76.9 | 4.53 | Upgrade
|
| Accounts Payable | 14.98 | 10.32 | 10.64 | 6.01 | 8.88 | 0.57 | 0.5 | 4.02 | 1 | 0.64 | Upgrade
|
| Deferred Revenue | 0 | 13.02 | 10.99 | 0 | 0.19 | 0 | 0 | 0 | 0 | 0 | Upgrade
|
| Current Debt | 68 | 111.26 | 54.7 | 0.2 | 4.01 | 0 | 0 | 2.76 | 0 | 0.21 | Upgrade
|
| Other Current Liabilities | 10.85 | 3.07 | 0.95 | 6.45 | 14.25 | 0.85 | 0.4 | 2.33 | 0.91 | 0.68 | Upgrade
|
| Total Current Liabilities | 93.83 | 137.66 | 77.28 | 12.66 | 27.33 | 1.41 | 0.9 | 9.1 | 1.91 | 1.53 | Upgrade
|
| Long-Term Debt | 3.13 | 4.42 | 31.24 | 0 | 0 | 0 | 0 | 7.21 | 9.74 | 0 | Upgrade
|
| Other Long-Term Liabilities | 0 | -127.59 | 0.1 | 0 | 0.04 | 0 | 0 | 0 | 0 | 2.2 | Upgrade
|
| Total Long-Term Liabilities | 3.13 | -123.17 | 31.34 | 0 | 0.04 | 0 | 0 | 7.21 | 9.74 | 2.2 | Upgrade
|
| Total Liabilities | 96.96 | 14.5 | 108.62 | 12.66 | 27.37 | 1.41 | 0.9 | 16.3 | 11.65 | 3.73 | Upgrade
|
| Total Debt | 71.13 | 115.68 | 85.94 | 0.2 | 4.01 | 0 | 0 | 9.96 | 9.74 | 0.21 | Upgrade
|
| Debt Growth | -38.51% | 34.61% | 43524.37% | -95.09% | - | - | - | 2.26% | 4603.63% | -67.03% | Upgrade
|
| Common Stock | 0.01 | 0.02 | 0.01 | 0.01 | 0 | 0 | 0 | 0 | 0 | 0 | Upgrade
|
| Retained Earnings | -938.69 | -860.68 | -655.49 | -513.18 | -433.15 | -135.84 | -125.85 | -112.83 | -69.67 | -58.86 | Upgrade
|
| Comprehensive Income | 49.53 | 5.09 | 0 | 0 | -0.6 | -0.09 | -0.14 | -0.09 | -0.13 | -0.11 | Upgrade
|
| Shareholders' Equity | -71.8 | 4.74 | 1.35 | 15.64 | -23.36 | 2.71 | 11.91 | 23.81 | 65.25 | 0.8 | Upgrade
|
| Total Liabilities and Equity | 25.16 | 19.24 | 109.97 | 28.3 | 4.01 | 4.12 | 12.82 | 40.11 | 76.9 | 4.53 | Upgrade
|
| Net Cash / Debt | -68.36 | -107.95 | -37.05 | 23.61 | -2.68 | 3.42 | 11.48 | 27.79 | 66.21 | 4.16 | Upgrade
|
| Net Cash / Debt Growth | - | - | - | - | - | -70.23% | -58.69% | -58.03% | 1492.68% | -60.30% | Upgrade
|
| Net Cash Per Share | -146.70 | -1546.16 | -1034.37 | 1100.30 | -229.45 | 3269.82 | 9362.03 | 22832.44 | 54490.89 | 3525.79 | Upgrade
|
| Working Capital | -81.13 | -118.43 | 20.45 | 13.76 | -24.85 | 2.61 | 11.61 | 30.63 | 74.96 | 2.98 | Upgrade
|
| Book Value Per Share | -154.08 | 67.89 | 37.62 | 728.78 | -1999.66 | 2590.19 | 9718.21 | 19562.28 | 53701.59 | 676.24 | Upgrade
|
Sources: The data provider is Financial Modeling Prep and the numbers are sourced from SEC filings.